TLDR:
- Eyenovia invests $50M in Hyperliquid (HYPE), becoming first public U.S. firm with native token treasury
- New CIO Hyunsu Jung will lead blockchain strategy and validator expansion
- Company to rebrand as Hyperion DeFi and adopt ticker HYPD alongside biotech operations
- Validator role through Anchorage aims to earn yield and secure Hyperliquid blockchain
Eyenovia has taken a historic step in merging traditional finance with Web3. The Nasdaq-listed biotech firm announced a $50 million investment to purchase HYPE tokens from the Hyperliquid blockchain. This move makes it the first U.S. public company to include a native crypto token in its treasury.
The company aims to secure validator status on the Hyperliquid network. Investors and crypto enthusiasts see this as a turning point for institutional blockchain adoption.
$50 Million Raised to Launch Hyperliquid Crypto Treasury
Eyenovia revealed its $50 million private placement agreement in a June 17 release. According to the company, this funding round was led by institutional accredited investors.
The proceeds will support its crypto reserve strategy, focused entirely on acquiring over 1 million HYPE tokens.
The company will issue convertible preferred stock and warrants, priced at $3.25 per share. If fully exercised, the warrants could bring in an additional $150 million. Eyenovia expects the transaction to close by June 20, pending standard conditions.
As part of this transition, Eyenovia appointed Hyunsu Jung as Chief Investment Officer and a new board member. His role will center on steering the crypto treasury initiative. Jung said the company selected HYPE due to its strong fundamentals and rising network performance.
The investment positions Eyenovia as one of the largest global validators on the Hyperliquid blockchain.
The firm also plans to stake its HYPE holdings through Anchorage Digital for secure management. This validator position will offer both yield opportunities and a role in maintaining the blockchain’s security.
Strategic Rebrand and Continued Operations
In parallel, Eyenovia will proceed with its biotech roadmap. It remains committed to the development of its Gen-2 Optejet device, which it aims to register with the FDA by September.
The company is also exploring commercial partnerships for the device’s rollout.
Alongside its crypto strategy, Eyenovia plans to rebrand to “Hyperion DeFi” and adopt the ticker “HYPD.” This shift signals a broader vision that aligns both its healthcare innovations and blockchain goals.
Nasdaq-listed Eyenovia just raised $50M to buy $HYPE tokens — becoming the first U.S. public company to hold a Web3-native token on its balance sheet.
Wall Street is no longer just watching.
They’re buying.— Crypto Patel (@CryptoPatel) June 18, 2025
Crypto commentator Crypto Patel noted that Wall Street is no longer watching from the sidelines. He shared that Eyenovia’s bold crypto move could inspire similar actions from other listed companies.
The post Nasdaq’s Eyenovia Bets on Hyperliquid, Becomes First Public U.S. Firm to Hold HYPE Tokens appeared first on Blockonomi.
Source: https://blockonomi.com/nasdaqs-eyenovia-bets-on-hyperliquid-becomes-first-public-u-s-firm-to-hold-hype-tokens/